Author details

Full Name

Hendrik Witt

Affiliation

ORCID

Career Start Year

2009

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36916248	Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study.	Neuro Oncol	2023
37287693	A multi-institutional retrospective pooled outcome analysis of molecularly annotated pediatric supratentorial <i>ZFTA-</i>fused ependymoma.	Neurooncol Adv	2023
33331885	Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study.	Neuro Oncol	2021
33135735	Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up.	Neuro Oncol	2021
31867747	Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters (DGONC) - a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14.	Neuropathol Appl Neurobiol	2020
31679042	Molecular characterization of histopathological ependymoma variants.	Acta Neuropathol	2020
31414211	MYCN amplification drives an aggressive form of spinal ependymoma.	Acta Neuropathol	2019
31022591	Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience.	Eur J Cancer	2019
30850560	Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series.	Oncologist	2019
29539639	DNA methylation-based classification of central nervous system tumours.	Nature	2018
30019219	Heterogeneity within the PF-EPN-B ependymoma subgroup.	Acta Neuropathol	2018
30053291	DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment.	Neuro Oncol	2018
29909548	Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.	Acta Neuropathol	2018
29996150	Molecular Diagnostics in Pediatric Brain Tumors: Impact on Diagnosis and Clinical Decision-Making - A Selected Case Series.	Klin Padiatr	2018
29489754	The landscape of genomic alterations across childhood cancers.	Nature	2018
29258295	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling.	Nature	2018
27858204	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants.	Acta Neuropathol	2017
28617804	Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification.	PLoS One	2017
28437838	Prognostic relevance of miR-124-3p and its target TP53INP1 in pediatric ependymoma.	Genes Chromosomes Cancer	2017
27556362	Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma.	Oncotarget	2016
27249765	Exploiting Laboratory Insights to Improve Outcomes of Pediatric Central Nervous System Tumors.	Am Soc Clin Oncol Educ Book	2016
26445087	Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors.	Brain Pathol	2016
26113311	Papillary Tumor of the Pineal Region: A Distinct Molecular Entity.	Brain Pathol	2016
26378811	Non-random aneuploidy specifies subgroups of pilocytic astrocytoma and correlates with older age.	Oncotarget	2015
25926029	Establishment of a patient-derived orthotopic osteosarcoma mouse model.	J Transl Med	2015
25965575	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups.	Cancer Cell	2015
25957288	Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype.	Clin Cancer Res	2015
26304884	Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape.	J Clin Oncol	2015
24553142	Epigenomic alterations define lethal CIMP-positive ependymomas of infancy.	Nature	2014
23852775	Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis.	Int J Cancer	2014
24651015	Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.	Cancer Cell	2014
23660940	Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytoma.	Acta Neuropathol	2013
23817572	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.	Nat Genet	2013
24139898	Hypermutation of the inactive X chromosome is a frequent event in cancer.	Cell	2013
23793099	BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1.	Nat Med	2013
23229276	Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal Â¹â¸F-FDG PET and gene expression analysis.	Journal of Cancer Research and Clinical Oncology	2013
23432646	Emerging insights into the ependymoma epigenome.	Brain Pathol	2013
23184418	Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma.	Acta Neuropathol	2013
23417712	Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas.	Acta Neuropathol	2013
22265402	Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations.	Cell	2012
22343890	Clonal selection drives genetic divergence of metastatic medulloblastoma.	Nature	2012
22340590	An animal model of MYC-driven medulloblastoma.	Cancer Cell	2012
22286061	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.	Nature	2012
22832583	Dissecting the genomic complexity underlying medulloblastoma.	Nature	2012
22832581	Subgroup-specific structural variation across 1,000 medulloblastoma genomes.	Nature	2012
22568867	Nestin expression identifies ependymoma patients with poor outcome.	Brain Pathol	2012
23007011	Molecular approaches to ependymoma: the next step(s).	Curr Opin Neurol	2012
23079654	Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.	Cancer Cell	2012
22160402	Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.	Acta Neuropathol	2012
21863243	A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat.	Acta Neuropathol	2011